Becomes Aribio's Third-Largest Shareholder
Joint Efforts on AR1001 Development, Production, and Approval

Chinese pharmaceutical company Fuxing Pharma will invest 42.5 billion won (27.5 million dollars) in Aribio, joining as a strategic shareholder. Following the exclusive global licensing contract for AR1001 worth approximately 7 trillion won signed in May, the two companies are further expanding their collaboration through this equity investment.


Aribio company logo image. Aribio

Aribio company logo image. Aribio

View original image

On July 3, Aribio announced that it had signed a strategic equity investment agreement worth about 42.5 billion won with Fuxing Pharma.


Under the agreement, Fuxing Pharma will initially invest approximately 11.5 billion won (7.5 million dollars). Following this, the company plans to pursue a second-stage equity investment of 31 billion won (20 million dollars) after completing required procedures.


This investment will make Fuxing Pharma the third-largest shareholder of Aribio, following Sorux (which is scheduled to change its name to Aribio Holdings) and Samjin Pharm.


This equity investment is a follow-up collaboration to the exclusive global licensing contract for AR1001 worth approximately 7 trillion won, signed in May. The company noted that it is rare for a global pharmaceutical company to become a strategic shareholder in such a short period after signing a large-scale technology export agreement.


AR1001 is a candidate drug being developed as the world’s first oral disease-modifying therapy (DMT) for Alzheimer’s disease. The company has completed dosing for patients in a global Phase 3 clinical trial conducted across 230 clinical sites in 13 countries and is now proceeding with subsequent steps.


The two companies plan to strengthen their collaboration across the development, approval, production, and commercialization stages of AR1001 as a result of this investment. They also intend to expand their partnership in the future to include follow-up new drug pipelines, immuno-oncology drugs, and vaccine platforms.



A representative from Aribio stated, “This strategic equity investment reflects Fuxing Pharma’s high evaluation of the technology behind AR1001 and Aribio’s growth potential,” adding, “We will jointly pursue global commercialization and continue to collaborate on innovative new drug development.”


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing